Does Melanoma Make You Sick? Signs of Advanced Disease

Early-stage melanoma confined to the skin rarely makes you feel unwell. You might notice a suspicious mole, but your body feels normal. The trouble starts when melanoma advances beyond the skin, spreading to lymph nodes or distant organs. At that point, it can cause a wide range of systemic symptoms, from persistent fatigue and unexplained weight loss to bone pain, seizures, or abdominal problems. What makes advanced melanoma particularly tricky is that many of these symptoms mimic other common conditions, and some spread silently for months before anything feels wrong.

Why Early Melanoma Feels Like Nothing

A melanoma that has not grown deep into the skin or reached the lymphatic system does not produce the kind of signals that make a person feel sick. There is no fever, no nausea, no fatigue. The only sign is usually a visual one: a changing mole, a new dark spot, or a patch of skin that looks different from everything around it. This is why dermatologists emphasize skin checks. The cancer announces itself on the surface long before it has the ability to affect the rest of your body. The catch is that people who do not examine their skin, or who have melanomas in hard-to-see locations, can miss this window entirely.

Some melanomas arise in locations that are inherently difficult to spot. Mucosal melanomas, which develop inside the mouth, nasal passages, or genital tract, grow in hidden areas and lack the early visual warning that skin melanomas provide. This contributes to delayed diagnosis and a worse outlook overall.¹ Oral mucosal melanoma, for instance, often progresses silently because it causes no pain in its early stages.² By the time symptoms appear, the disease has usually advanced considerably.³

The Transition to Feeling Sick

The shift from “I feel fine” to “something is wrong” typically corresponds to melanoma reaching the lymph nodes or spreading to distant organs. Once melanoma cells settle into lymph nodes, there is a significantly higher risk that microscopic disease has already seeded elsewhere in the body. Patients with confirmed lymph node involvement face poorer survival precisely because of that hidden distant spread.⁴

This is also where the immune system starts losing ground. Research on patients with metastatic melanoma has shown that the disease drives a systemic shift in the immune response. The tumor itself does not flood the blood with inflammatory molecules directly, but it releases signals that push the immune system into a less effective mode of operation. In patients with active metastases, levels of certain immune-signaling proteins were significantly higher than in patients whose melanoma had been surgically removed, suggesting the tumor’s presence actively distorts the immune environment.⁵ This chronic immune disruption helps explain the fatigue, malaise, and general decline that many patients with advanced melanoma experience even before a specific organ-related symptom appears.

When Melanoma Reaches the Brain

Melanoma has a well-known affinity for the brain, and brain metastases are among the most feared complications. Symptoms depend on where in the brain the tumor lands. A metastasis in the occipital lobe might cause sudden visual disturbances that mimic a stroke, as documented in a case where a 48-year-old woman presented with acute visual field loss that was initially suspected to be a stroke but turned out to be metastatic melanoma.⁶ Other common neurological signs include headaches, weakness on one side of the body, difficulty speaking, and seizures.

Brain metastases can also appear or worsen during treatment. In a case series of patients with stage IV melanoma receiving immunotherapy, several developed severe neurological symptoms including headache, one-sided weakness, and speech difficulties. Some of these patients had not yet been diagnosed with brain involvement when the symptoms emerged. Two patients with pre-existing brain metastases developed brain swelling and bleeding during treatment. Four of the five patients in that series ultimately died from neurological complications.⁷

PET/CT scans paired with brain MRI play an important role in catching brain spread early. In one study, brain MRI revealed brain metastases in about 7% of melanoma patients being evaluated before surgery for palpable lymph node disease.⁸ PET/CT scans showing high overall metabolic activity may also help predict which patients are most likely to develop brain metastases later, flagging those who might benefit from closer monitoring.⁹

Gut and Liver Symptoms

Melanoma can spread to virtually any organ in the abdomen, including the stomach, small intestine, and liver. What makes gastrointestinal metastases deceptive is that they often remain clinically silent for long stretches, sometimes appearing years after the original melanoma was treated.¹⁰ When symptoms do develop, they range from vague abdominal discomfort and nausea to more alarming signs like bleeding, obstruction, or perforation. One case report described a patient whose gastrointestinal discomfort was the very first indication that melanoma had spread to the liver, stomach, and duodenum.¹¹ Another patient avoided medical attention during the silent phase and eventually presented to the emergency department with signs of small bowel perforation, a surgical emergency.¹²

Uveal melanoma, which originates in the eye rather than the skin, has a distinct and particularly aggressive pattern of liver spread. Nearly half of uveal melanoma patients eventually develop metastatic disease, almost always involving the liver, and survival after that diagnosis is usually less than a year.¹³ Microscopic studies of liver tissue from patients who died of uveal melanoma metastases found that the tiniest tumor clusters, invisible to standard imaging, were present in nine out of ten patients. These microscopic deposits lacked blood vessels and were not actively dividing, suggesting a dormant phase before the disease explodes into detectable, symptomatic metastases.¹⁴

Bone Pain and Fracture Risk

When melanoma spreads to bone, the most common symptom is pain at the site of the metastasis. But bone metastases can also weaken the skeleton enough to cause pathologic fractures, meaning bones break under forces that healthy bone would handle easily. A retrospective study of 481 melanoma patients with bone metastases found that by one year, over half had experienced a skeletal-related event such as a fracture, the need for radiation to bone, or spinal cord compression. About 28% had a pathologic fracture specifically.¹⁵

Bone metastases can also cause dangerous elevations in blood calcium. As melanoma destroys bone tissue, calcium leaks into the bloodstream. The tumor may also produce proteins that increase bone breakdown and reduce the kidneys’ ability to clear calcium, compounding the problem.¹⁶ High calcium levels cause their own symptoms: confusion, excessive thirst, constipation, nausea, and in severe cases, heart rhythm abnormalities. A patient who suddenly develops these symptoms alongside known melanoma should be evaluated for bone involvement and hypercalcemia quickly.

The Heart as a Hidden Target

One of the more surprising facts about advanced melanoma is how frequently it reaches the heart. Melanoma involves the heart or pericardium in more than half of metastatic cases at autopsy. Yet cardiac metastases are rarely diagnosed during life because they often produce no symptoms at all, or produce symptoms that overlap with many other conditions like shortness of breath or fluid retention.¹⁷ When symptoms do appear, they can include chest pain, irregular heartbeat, or pericardial effusion, which is fluid buildup around the heart. Because clinicians are not routinely imaging the heart in melanoma follow-up, many of these cases are discovered incidentally or posthumously.

Paraneoplastic Syndromes

Sometimes melanoma makes you sick in ways that have nothing to do with a tumor physically pressing on or invading an organ. Paraneoplastic syndromes are conditions caused by the immune system’s misdirected response to the cancer. The tumor triggers the production of antibodies that accidentally attack healthy tissues, causing symptoms far from the tumor itself.

The most recognized paraneoplastic syndrome in melanoma is melanoma-associated retinopathy. Patients develop sudden night blindness, visual field defects, and shimmering visual phenomena, often while their actual visual sharpness and color vision remain relatively intact. The antibodies the immune system generates against the melanoma cross-react with proteins in the retina, damaging it.¹⁸ Beyond the eyes, melanoma-related paraneoplastic syndromes can affect the brain (encephalitis, cerebellar degeneration), the peripheral nerves, and even the skin (vitiligo-like depigmentation, inflammatory muscle disease).¹⁹ These are individually rare, but they matter because they can be the first sign that melanoma has metastasized, and they are easily mistaken for unrelated neurological or autoimmune diseases.

LDH and What Blood Tests Reveal

If you have advanced melanoma, your oncologist will almost certainly track your lactate dehydrogenase level, commonly abbreviated LDH. This enzyme spills into the bloodstream when cells are damaged or dying rapidly, and elevated LDH is one of the strongest blood-based indicators that melanoma is progressing. It has been established as both a predictive and prognostic marker: patients with higher LDH tend to respond less well to treatment and have shorter survival.²⁰

In one study of metastatic melanoma patients, each increase of 100 IU/L in baseline LDH was associated with a meaningful drop in both progression-free and overall survival.²¹ LDH is not specific to melanoma and can be elevated for many reasons, so a high reading alone does not confirm progression. But a rising trend in someone with known melanoma is a red flag that warrants further imaging and evaluation.

Feeling Sick from Treatment, Not Just Disease

A complication that confuses many patients is separating the symptoms of advanced melanoma from the side effects of treatment. Modern melanoma therapies, while dramatically effective, can produce symptoms that look a lot like the disease itself.

The most striking example is pyrexia syndrome from the combination of dabrafenib and trametinib, a targeted therapy used in melanoma with specific genetic mutations. Across clinical trials involving over a thousand patients, roughly 61% developed fever, and about 6% had severe episodes.²² This is fever without any infection. If it is not managed promptly, it can escalate into dehydration, low blood pressure, and organ-related complications.²³ Data from the COMBI-AD trial in the adjuvant setting showed even higher rates, with 63% of patients developing fever of any severity and 5% experiencing serious events.²⁴

Immunotherapy drugs, including checkpoint inhibitors, produce their own set of side effects. Common treatment-related symptoms reported by Canadian patients with advanced melanoma included nausea, fatigue, diarrhea or constipation, and skin rashes. These symptoms affected physical functioning, daily activities, and social life.²⁵ Distinguishing treatment-related fatigue from disease-related fatigue, or drug-induced nausea from gastrointestinal metastases, is a real challenge. Patients should report new or worsening symptoms promptly so clinicians can determine whether the disease is progressing or the treatment needs adjustment.

The Broader Toll on Daily Life

Beyond the specific organ-by-organ symptoms, advanced melanoma takes a cumulative toll that affects nearly every dimension of a person’s life. A qualitative study of Canadian patients found that by the time they reached an advanced stage, their overall functioning and quality of life had been greatly diminished. Patients described the impact in terms of physical pain and disability, emotional distress, reduced interactions with friends and family, and significant burden on caregivers.²⁶

Treatment itself adds another layer. Research tracking quality-of-life scores in patients receiving ipilimumab, an immunotherapy drug, found meaningful deterioration in health-related quality of life within the first 10 to 12 weeks of treatment.²⁷ Some of this decline recovers if the treatment works, but for patients who do not respond, the side effects stack on top of disease progression. The psychological weight of living with a cancer known for its aggressiveness compounds the physical burden in ways that quality-of-life questionnaires only partially capture.

Surveillance Imaging and Finding Spread Before Symptoms

One practical question for anyone treated for melanoma is whether routine imaging after surgery can catch spread before symptoms develop. PET/CT scans combined with brain MRI have shown clear value in this setting. In one study of patients with palpable lymph node metastases, PET/CT changed the surgical plan in over a third of cases by revealing additional disease. Patients without extra lesions on PET/CT had two-year overall survival of 84%, compared with 56% for those with additional metastases.⁸

For brain-specific surveillance, the data is more nuanced. A study of stage 3 melanoma patients in post-operative follow-up found that truly asymptomatic brain-only recurrence detected by routine MRI was uncommon, occurring in just one of 43 patients scanned. Most brain recurrences were either already symptomatic or accompanied by widespread disease.²⁸ This does not mean brain imaging is useless, but it does suggest that the odds of catching a silent, treatable brain metastasis through routine scans alone are lower than many patients hope.

Palliative Radiation for Symptom Control

When advanced melanoma causes localized pain or neurological problems that cannot be addressed with systemic therapy alone, radiation can be a powerful tool for symptom relief. A study of patients with bone metastases from melanoma found that about 85% of treated bone lesions responded to palliative radiation, with pain reduced or eliminated. Spinal cord compression, one of the most disabling complications of bone spread, responded to radiation in about 71% of cases.²⁹ Separate research found that higher radiation doses were associated with longer-lasting palliation and improved survival in patients with non-brain melanoma metastases, reinforcing that radiation is worth considering rather than dismissing in a cancer historically considered resistant to it.³⁰

The perception that melanoma does not respond to radiation is an outdated oversimplification. While melanoma cells may be somewhat less sensitive to conventional low-dose-per-session radiation than some other cancers, the clinical data on palliation tells a different story. For someone dealing with painful bone metastases or a tumor compressing the spinal cord, radiation frequently delivers meaningful relief and should be part of the conversation with the oncology team.